No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GH Guardant Health
- 22.510
- -1.060-4.50%
Close May 22 16:00 ET
- 22.920
- +0.410+1.82%
Post 19:16 ET
2.75BMarket Cap-5742P/E (TTM)
23.620High22.400Low3.14MVolume23.540Open23.570Pre Close71.38MTurnover2.86%Turnover RatioLossP/E (Static)122.37MShares41.06052wk High40.34P/B2.47BFloat Cap15.81052wk Low--Dividend TTM109.82MShs Float181.070Historical High--Div YieldTTM5.18%Amplitude15.810Historical Low22.742Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. William Blair 44th Annual Growth Stock Conference in
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Lexaria Bioscience (LEXX) and Guardant Health (GH)
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
Tuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's (NASDAQ:GH) experimental blood test for colorectal cancer, suggesting it might not detect some tumor types that could
Express News | Guardant Health Shares Are Trading Lower After FDA Staff in a Briefing Said the Company's Test May Fail to Detect Some Types of Advanced Adenomas in Patients
Guardant Health Slips as FDA Comments on Cancer Screening Test
Comments
Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)? 1
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades $Snowflake(SNOW.US$ to Peer Perform From Outperform
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
18
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg